These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19218537)

  • 1. The vaptans ante portas: a status report.
    Gross P; Marczewski T; Herbrig K
    Nephrol Dial Transplant; 2009 May; 24(5):1371-3. PubMed ID: 19218537
    [No Abstract]   [Full Text] [Related]  

  • 2. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conivaptan Yamanouchi.
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conivaptan: promise of treatment in heart failure.
    Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
    Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaptans and the treatment of water-retaining disorders.
    Quittnat F; Gross P
    Semin Nephrol; 2006 May; 26(3):234-43. PubMed ID: 16713496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vaptans: just landed. But how was the trip?
    Gross P
    Nephrol Dial Transplant; 2010 May; 25(5):1367-8. PubMed ID: 20200008
    [No Abstract]   [Full Text] [Related]  

  • 7. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
    Yamamura Y; Sato O; Fujiki H
    Nihon Rinsho; 2007 May; 65 Suppl 5():164-8. PubMed ID: 17571379
    [No Abstract]   [Full Text] [Related]  

  • 8. Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients.
    Lehrich RW; Greenberg A
    J Intensive Care Med; 2012; 27(4):207-18. PubMed ID: 21571754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conivaptan (Vaprisol) for hyponatremia.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):51-2. PubMed ID: 16785851
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P
    Arch Mal Coeur Vaiss; 2006 Mar; 99(3):215-20. PubMed ID: 16618024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Disorders of body water regulation and the therapy--vasopressin antagonists].
    Ishikawa S; Saito T
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1654-9. PubMed ID: 9410978
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.
    Chen S; Jalandhara N; Batlle D
    Nat Clin Pract Nephrol; 2007 Feb; 3(2):82-95. PubMed ID: 17251996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists.
    Elhassan EA; Schrier RW
    Curr Opin Nephrol Hypertens; 2011 Mar; 20(2):161-8. PubMed ID: 21252664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyponatremia in heart failure: time for a trial.
    Goldsmith SR
    J Card Fail; 2013 Jun; 19(6):398-400. PubMed ID: 23743488
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy?
    Filippatos G; Parissis JT
    J Card Fail; 2008 Oct; 14(8):648-50. PubMed ID: 18926435
    [No Abstract]   [Full Text] [Related]  

  • 17. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
    Ghali JK; Tam SW
    J Card Fail; 2010 May; 16(5):419-31. PubMed ID: 20447579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyponatremia and outcomes in patients with heart failure.
    Goldsmith SR
    Heart; 2012 Dec; 98(24):1761-2. PubMed ID: 23204533
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
    Greenberg A
    Am J Kidney Dis; 2007 Dec; 50(6):904-7. PubMed ID: 18037090
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on tolvaptan for the treatment of hyponatremia.
    Dasta JF; Chiong JR; Christian R; Friend K; Lingohr-Smith M; Lin J; Cassidy IB
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):399-410. PubMed ID: 22971027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.